Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

238 Applying Pharmacogenomics in Therapeutics
63. Hizawa N. Pharmacogenetics of beta2-agonists. Allergology International 2011;60:​
239–46.
64. Konno S, Makita H, Hasegawa M, et al. Beta2-adrenergic receptor polymorphisms
as a determinant of preferential bronchodilator responses to beta2-agonist and anticholinergic
agents in Japanese patients with chronic obstructive pulmonary disease.
Pharmacogenetics and Genomics 2011;21:687–93.
65. Hizawa N, Makita H, Nasuhara Y, et al. Beta2-adrenergic receptor genetic polymorphisms
and short-term bronchodilator responses in patients with COPD. Chest
2007;132:1485–92.
66. Mokry M, Joppa P, Slaba E, et al. Beta2-adrenergic receptor haplotype and bronchodilator
response to salbutamol in patients with acute exacerbations of COPD. Medical
Science Monitor 2008;14:CR392–8.
67. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development for
asthma and chronic obstructive pulmonary disease. Expert Opinion on Investigational
Drugs 2005;14:775–83.
68. Yelensky R, Li Y, Lewitzky S, et al. A pharmacogenetic study of ADRB2 polymorphisms
and indacaterol response in COPD patients. The Pharmacogenomics Journal
2012;12:484–8.
69. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches.
Nature Medicine 2012;18:716–25.
70. Fanta CH. Asthma. The New England Journal of Medicine 2009;360:1002–14.
71. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines
major subphenotypes of asthma. American Journal of Respiratory and Critical Care
Medicine 2009;180:388–95.
72. Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: Their pathological roles in allergic
diseases and their potential in developing new therapies. Current Drug Targets 2002;​
1:263–9.
73. Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generation
and mast cell effector function in mice deficient in IL-4 and IL-13. The Journal of
Immunology 2005;174:7716–24.
74. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4
in experimental asthma. Science 1998;282:2261–3.
75. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trends
in Molecular Medicine 2004;10:493–9.
76. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care
use, and mortality in the United States, 2001–2010. NCHS data brief, no. 94. National
Center for Health Statistics, Hyattsville, ML; 2012.
77. Janssens T, Ritz T. Perceived triggers of asthma: Key to symptom perception and management.
Clinical and Experimental Allergy 2013;43:1000–8.
78. Ritz T, Steptoe A, Bobb C, Harris AH, Edwards M. The asthma trigger inventory:
Validation of a questionnaire for perceived triggers of asthma. Psychosomatic Medicine
2006;68:956–65.
79. Ritz T, Kullowatz A, Bobb C, et al. Psychological triggers and hyperventilation symptoms
in asthma. Annals of Allergy, Asthma and Immunology 2008;100:426–32.
80. Ege MJ, Mayer M, Normand AC, et al. Exposure to environmental microorganisms and
childhood asthma. The New England Journal of Medicine 2011;364:701–9.
81. Karvonen AM, Hyvarinen A, Gehring U, et al. Exposure to microbial agents in
house dust and wheezing, atopic dermatitis and atopic sensitization in early childhood:
A birth cohort study in rural areas. Clinical and Experimental Allergy 2012;​
42:1246–56.
82. Koh YY, Kim CK. The development of asthma in patients with allergic rhinitis. Current
Opinion in Allergy and Clinical Immunology 2003;3:159–64.